10-Jun-2026
No headlines found.
Quest Analytics Expands Leadership Team with Appointment of Chris Lance as Chief Product Officer
PRNewswire (Tue, 12-May 7:00 AM ET)
Evolent Announces First Quarter 2026 Results
PRNewswire (Thu, 7-May 7:00 AM ET)
Evolent To Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
PRNewswire (Tue, 7-Apr 4:30 PM ET)
Evolent announces appointment of Archie Mayani as chief product officer
PRNewswire (Thu, 19-Mar 8:45 AM ET)
Foodsmart Appoints Cityblock Health Co-Founder and CEO Dr. Toyin Ajayi to Board of Directors
PRNewswire (Wed, 18-Mar 9:12 AM ET)
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Evolent Health Class A trades on the NYSE stock market under the symbol EVH.
As of June 10, 2026, EVH stock price declined to $4.47 with 1,844,291 million shares trading.
EVH has a beta of 2.26, meaning it tends to be more sensitive to market movements. EVH has a correlation of 0.14 to the broad based SPY ETF.
EVH has a market cap of $502.79 million. This is considered a Small Cap stock.
Last quarter Evolent Health Class A reported $496 million in Revenue and -$.02 earnings per share. This fell short of revenue expectation by $-37 million and exceeded earnings estimates by $.05.
In the last 3 years, EVH traded as high as $35.00 and as low as $2.10.
The top ETF exchange traded funds that EVH belongs to (by Net Assets): VTI, IWM, VXF, FNDA, IWN.
EVH has underperformed the market in the last year with a return of -47.3%, while SPY returned +22.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in EVH shares. However, EVH has outperformed the market in the last 3 month and 2 week periods, returning +47.0% and +16.7%, while SPY returned +7.2% and -3.4%, respectively. This indicates EVH has been having a stronger performance recently.
EVH support price is $4.48 and resistance is $4.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVH shares will trade within this expected range on the day.